Market Overview

UPDATE: Jefferies Raises PT to $10 on Amedisys, Maintains Neutral on Reimbursement Uncertainty

Related AMED
Benzinga's Top Initiations
Worst Performing Industries For August 20, 2015
DaVita's Strategic Acquisitions Impress, Debt Drags (Zacks)

Jefferies maintained Amedisys (NASDAQ: AMED) with a Hold and raised the price target from $9.00 to $10.00.

Jefferies analyst Brian Tanquilut wrote, "We continue to have a cautious view on AMED given our belief that ongoing budget discussions in DC could yield incremental rate cuts for home nursing providers such as AMED. Additionally, we are concerned that ongoing volume pressure (from persistent weakness in recertifications) will impact AMED's ability to offset upcoming rate cuts and drive LT EPS growth."

Amedisys closed at $11.19 on Wednesday.

Latest Ratings for AMED

Sep 2015Wells FargoInitiates Coverage onOutperform
Jul 2015Mizuho SecuritiesInitiates Coverage onBuy
Jun 2015JefferiesUpgradesHoldBuy

View More Analyst Ratings for AMED
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings


Related Articles (AMED)

View Comments and Join the Discussion!

Get Benzinga's Newsletters